There is no product in the shopping cart, buy it!
Equipped with top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience in the field of glycoprotein development, Creative Biolabs employs several highly efficient glyco-engineered platforms and chemical or (chemo) enzymatic methods for the development of glycoprotein vaccine candidate. We are fully competent and dedicated to serving as your one-stop-shop for glycoprotein vaccine candidate development and characterizations.
HCV infection remains a major public health issue with some 185 million individuals infected with HCV worldwide. Although the introduction of several direct‑acting antiviral agents, there is an urgent need for an effective prophylactic HCV vaccine. HCV envelope glycoproteins E1 and E2 form a heterodimer on the surface of HCV. E2 interacts directly with cellular receptors CD81 and scavenger receptor class B member 1 to mediate viral entry. E2 is an optimal candidate for HCV vaccine development because it possesses most neutralizing antibody-recognized epitopes. Therefore, a number of HCV vaccine candidates based on E2 have been developed.
Development of a vaccine against human CMV infection is a major public health priority. So far, the most widely studied vaccine is a subunit vaccine based on the viral envelope glycoprotein B (gB). CMV gB is synthesized as a polypeptide with 906- or 907-aa in length that undergoes extensive posttranslational modification, including glycosylation at N- and O-linked sites. gB remains an important component of all CMV vaccines currently in development.
Human RSV is the main cause of severe lower respiratory tract infections among infants and young children worldwide. Great efforts on the development of RSV vaccine have been done to bring safe and effective vaccines to the market. Subunit-based vaccines are considered for important target group. The viral envelope glycoproteins, the fusion (F) protein and the attachment glycoprotein (G) protein, are involved in virus entry into the target cell. G protein is the receptor-binding protein, while F protein has membrane fusion activity. Both proteins have been shown to elicit virus-neutralizing antibodies. Clearly, antibodies directed to G protein interfere with binding of RSV virions to cellular receptors, while antibodies directed to F protein inhibit viral membrane fusion. Therefore, F protein and G protein are promising antigens in the development of a subunit vaccine against RSV.
Fig.1 Epitopes present on two major conformations of the RSV F glycoprotein. (Graham, 2019)
The ability to modify, manipulate and incorporate in a site-specific way glycosidic residues on proteins is widely accepted as one of the most important challenges. Glycosylation of protein by the natural cell is a prevalent post-translational modification (PTM) that results in complex mixtures of constructs with different glycoforms. With proven experience in glycoscience, Creative Biolabs has established glyco-engineered mammalian cell expression system, glyco-engineered pichia pastoris expression system and glyco-engineered plant-based expression system for the development of glycoprotein vaccine candidates.
Glycoforms produced in vivo are difficult to purify and characterize and different glycoforms can have different biological functions. Chemical site-specific glycosylation methods can resolve issues of homogeneous glycoprotein vaccine candidates. Site-specific strategies allow for the synthesis of defined glycoproteins with a precisely controlled epitope. With Ph.D. level scientists and substantial experience in employing chemical and (chemo)enzymatic strategies for site-specific glycosylation of proteins, we ensure high-purity homogeneous glycoprotein vaccine candidates which are obtained by highly efficient and simple operation under mild conditions.
Creative Biolabs has accumulated extensive experience in custom glycoprotein synthesis through glycoprotein remodelling, native chemical ligation (NCL), expressed protein ligation (EPL), Staudinger ligation or sugar-assisted ligation. We have developed a highly specialized platform as well as various comprehensive and innovative protocols for the synthesis of well-defined glycoprotein vaccine candidates up to 150 amino acids in length.
As a leading specialist in in glycoscience, Creative Biolabs excels at the glycodesign and the development of glycoprotein. We offer custom glycoprotein vaccine candidate development according to our clients’ needs and delivered in a timely manner. For more detailed information, please feel free to contact us or directly send us an inquiry.